We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Two TV Ads Earn Eli Lilly a Slap From FDA, But Lilly Makes Good
Two TV Ads Earn Eli Lilly a Slap From FDA, But Lilly Makes Good
All is well between Eli Lilly and the FDA after the agency’s Office of Prescription Drug Promotion (OPDP) admonished the drugmaker for not submitting two direct-to-consumer TV advertisements for its migraine drug Emgality (galcanezumab) to FDA for consideration before the ads aired.